Health state utility data in Cystic Fibrosis: A systematic review

Mohindru, Bishal, Turner, David ORCID: https://orcid.org/0000-0002-1689-4147, Sach, Tracey ORCID: https://orcid.org/0000-0002-8098-9220, Bilton, Diana, Carr, Siobhan, Archangelidi, Olga, Bhadhuri, Arjun and Whitty, Jennifer ORCID: https://orcid.org/0000-0002-5886-1933 (2020) Health state utility data in Cystic Fibrosis: A systematic review. PharmacoEconomics - Open, 4 (1). 13–25. ISSN 2509-4262

Preview	PDF (Health_state_utility_data_in_Cystic_Fibrosis_AAM) - Accepted Version Download (1MB) | Preview
Preview	PDF (Published_Version) - Published Version Available under License Creative Commons Attribution Non-commercial. Download (883kB) | Preview

Abstract

Introduction: Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease progression. However, little is known about the health state utility (HSU) associated with CF disease states, adverse events, and changes in disease severity. Although HSU data have contributed to existing health economic modelling studies, a lack of such data have been highlighted. This systematic review aims to provide a summary of HSU-related research in CF and highlight related research gaps. Methods: Online searches were performed in six databases and studies in any of the following categories were included: (1) estimation of HSUs in CF; (2) mapping studies between patient-reported outcome measures (PROMs) and HSUs; (3) economic evaluations on the management of CF that report primary HSU data; and (4) any CF clinical trial that reported HSU as an outcome. Results: A total of 17 studies were reviewed, of which 12 provided HSU values for specific CF populations. The remaining five articles provided HSU data that were broken down by CF relevant health states, including lung transplantations, pulmonary exacerbation (PEx) events and forced expiratory volume in 1 s (FEV 1). Conclusion: Current HSU data in CF are limited and there is considerable scope for further research, both in providing HSU values for CF and in investigating methods for HSU elicitation/evaluation in CF populations.

Item Type:	Article
Uncontrolled Keywords:	health policy,pharmacology (medical),pharmacology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2719
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group Faculty of Medicine and Health Sciences > Research Centres > Norwich Institute for Healthy Aging Faculty of Medicine and Health Sciences > Research Centres > Population Health
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	09 May 2019 09:30
Last Modified:	19 Oct 2023 02:26
URI:	https://ueaeprints.uea.ac.uk/id/eprint/70878
DOI:	10.1007/s41669-019-0144-1

Downloads

Actions (login required)

View Item